Patiromer Calcium
drug drugOn this page
Also known as Patiromere calciquePatiromero calcicoRLY-5016RLY5016
Summary
Patiromer Calcium (CHEMBL2107840) is an approved small molecule (ATC V03AE09); indicated across 1 condition.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V03AE09
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107840 |
| Name | Patiromer Calcium |
| Type | Small molecule |
| Max phase | 4 |
| ATC | V03AE09 |
Also known as: Patiromer calcium, Patiromere calcique, Patiromero calcico, RLY-5016, RLY5016, PATIROMER CALCIUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.